Quick Takeaways
- Deep Track Capital, LP filed SCHEDULE 13G/A for Oruka Therapeutics, Inc. Common stock, $0.001 Par Value (ORKA).
- Disclosed ownership: 4.5%.
- Date of event: 31 Dec 2025.
Deep Track Capital, LP - 31 Dec 2025 SCHEDULE 13G/A Report for Oruka Therapeutics, Inc. Common stock, $0.001 Par Value (ORKA)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- ORKA
- Shares outstanding
- 48,355,928 shares
- Disclosed Ownership
- 2,161,510 shares
- Ownership
- 4.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Feb 2026, 08:50:18 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 13 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Deep Track Capital, LP disclosed 4.5% ownership in Oruka Therapeutics, Inc. Common stock, $0.001 Par Value (ORKA) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 13 May 2025.
- Current filing was accepted on 13 Feb 2026, 08:50.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 4.5% | 2,161,510 | 0 | 2,161,510 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 3.9% | 1,899,455 | 0 | 1,899,455 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 4.5% | 2,161,510 | 0 | 2,161,510 | /s/ David Kroin | David Kroin | |
| Deep Track Special Opportunities Fund, LP. | 0.54% | 262,055 | 0 | 262,055 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser of Deep Track Special Opportunities Fund, LP |